Clinical trial in Australia, in collaboration with international counterparts.
Find out more
- Funding Opportunity website:
- grants.gov.au/Go/Show?GoUuid=030340B5-DE2F-7579-35FC-B4AD7085B7E4
Clinical trial in Australia, in collaboration with international counterparts.
To find out more, register for the HTSA MRFF Catalyst Grant Scheme Launch Webinar Wednesday May 10th, 12pm-1pm ACST
Applications will be open from 1 July 2021 at 9 am ACST and be closed at 30 July 2021 at 4 pm ACST.
Photo by Nathan Anderson on Unsplash.
Minimum Data closes at 5:00 pm (ACT Local Time) on 22 June 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on 23 February 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on 20 April 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on 29 June 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on 29 June 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on 29 June 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on 29 June 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on 29 June 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on 16 February 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on 9 Feb 2022
Minimum Data closes at 5:00 pm (ACT Local Time) on Wednesday 02 February 2022.
Minimum Data closes at 5:00 pm (ACT Local Time) on Wednesday 2 February 2022.
Minimum data due 1700 ACT local time, 24 November 2021.
Minimum Data closes at 5:00 pm (ACT Local Time) on 9 February 2022.
Minimum Data closes at 5:00 pm (ACT Local Time) on 9 February 2022.
Minimum Data closes at 5:00 pm (ACT Local Time) on 25 Jan 2022.
Minimum Data closes at 5:00 pm (ACT Local Time) on 16 February 2022.
Minimum Data closes at 5:00 pm (ACT Local Time) on 2 February 2022.
Minimum Data Dates:
Round 1: 5pm ACT local time on 25 August 2021
Round 2: 5pm ACT local time on 2 February 2022
Expressions of interest close 19 April 2021.
Minimum Data: 5pm ACT local time on 7 July 2021
Expressions of interest are open and will need to be submitted by 17th December 2021 by 5pm by email to hcffoundation@hcf.com.au
Expressions of interest close 10 March 2021
Strategic investment in data registries, biobanks and data linkage platforms for primary health care in a range of settings.
Projects should aim to improve medicine use and medicine intervention by pharmacists in primary health and transitions of care.
Stream 1: utilise existing evidence to develop or improve approaches for the early diagnosis of ovarian cancer, cancers of the pancreas, liver cancer or lung cancer that have a clinically feasible pathway to implementation
Stream 2: enable approaches for the early diagnosis of cancers with unknown primary site that have a clinically feasible pathway to implementation.
Development of novel interventions, including therapeutics and devices, to prevent cardiovascular disease and stroke; develop novel treatments and devices to improve outcomes; and conduct small-scale development projects to establish feasible, evidence-based approaches aimed at improving survivorship and reducing morbidity.
$17.5 million across 4 streams.